[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100392638":3},{"organization":4,"armGroups":7,"interventions":38,"overallOfficials":58,"centralContacts":63,"locations":73,"responsibleParty":92,"collaborators":94,"id":100,"slug":101,"hasResults":102,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":44,"eligibilityCriteria":106,"healthyVolunteers":102,"sex":107,"minAge":108,"maxAge":44,"enrollmentInfo":109,"targetDuration":44,"studyType":112,"phases":113,"briefSummary":115,"conditions":116,"keywords":44,"overallStatus":75,"whyStopped":44,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":127},{"fullName":5,"class":6},"Stanford University","OTHER",[8,17,21,25,29,32,35],{"label":9,"type":10,"description":11,"interventionNames":12},"d-limonene -2gram","EXPERIMENTAL","2 gram d-limonene orally, once daily delivered during chemoradiation",[13,14,15,16],"Drug: D-Limonene Gelcaps","Radiation: Intensity modulated radiotherapy (IMRT)","Drug: Cisplatin","Other: Xerostomia questionnaire",{"label":18,"type":10,"description":19,"interventionNames":20},"d-limonene -4gram","4 gram d-limonene orally, as 2 grams 2 times daily delivered during chemoradiation",[13,14,15,16],{"label":22,"type":10,"description":23,"interventionNames":24},"d-limonene -6gram","6 gram d-limonene orally, as 3 grams 2 times daily delivered during chemoradiation",[13,14,15,16],{"label":26,"type":10,"description":27,"interventionNames":28},"d-limonene -8gram","8 gram d-limonene orally, as 4 grams 2 times daily delivered during chemoradiation",[13,14,15,16],{"label":30,"type":10,"description":23,"interventionNames":31},"de-escalation dose d-limonene -6gram",[13,14,15,16],{"label":33,"type":10,"description":19,"interventionNames":34},"de-escalation dose d-limonene -4gram",[13,14,15,16],{"label":36,"type":10,"description":11,"interventionNames":37},"de-escalation dose d-limonene -2gram",[13,14,15,16],[39,45,50,54],{"type":40,"name":41,"description":42,"armGroupLabels":43,"otherNames":44},"DRUG","D-Limonene Gelcaps","Administered orally at 2 to 8 grams daily",[9,18,22,26,36,33,30],null,{"type":46,"name":47,"description":48,"armGroupLabels":49,"otherNames":44},"RADIATION","Intensity modulated radiotherapy (IMRT)","Standard of Care -All patients will receive standard radiation treatment of 66 to 70 Gy given in 33 to 35 fractions (2 to 2.12 Gy\u002Ffractions) over 6.5 to 7 weeks.",[9,18,22,26,36,33,30],{"type":40,"name":51,"description":52,"armGroupLabels":53,"otherNames":44},"Cisplatin","Standard of Care -Cisplatin as 100 mg\u002Fm2 IV",[9,18,22,26,36,33,30],{"type":6,"name":55,"description":56,"armGroupLabels":57,"otherNames":44},"Xerostomia questionnaire","Xerostomia questionnaire consists of 4 items on dryness while eating\u002Fspeaking and 4 on dryness at rest. Patients rate each symptom on an 11 point ordinal Likert scale from 0 to 10, with higher scores indicating greater xerostomia",[9,18,22,26,36,33,30],[59],{"name":60,"affiliation":61,"role":62},"Quynh-Thu Le","Stanford Universiy","PRINCIPAL_INVESTIGATOR",[64,69],{"name":65,"role":66,"phone":67,"phoneExt":44,"email":68},"Camellia Djebroun","CONTACT","650-736-5564","cdjebrou@stanford.edu",{"name":70,"role":66,"phone":71,"phoneExt":44,"email":72},"Kelly Huang","650-724-4606","kelhuang@stanford.edu",[74],{"facility":5,"status":75,"city":76,"state":77,"zip":78,"country":79,"countryCode":80,"cosmosGeoPoint":81,"geoPoint":86,"contacts":87},"RECRUITING","Stanford","California","94305","United States","US",{"type":82,"coordinates":83},"Point",[84,85],-122.16608,37.42411,{"lat":85,"lon":84},[88,89,90],{"name":65,"role":66,"phone":67,"phoneExt":44,"email":68},{"name":70,"role":66,"phone":71,"phoneExt":44,"email":72},{"name":91,"role":62,"phone":44,"phoneExt":44,"email":44},"Quynh-Thu Le, M.D.",{"type":93,"investigatorFullName":44,"investigatorTitle":44,"investigatorAffiliation":44,"oldNameTitle":44,"oldOrganization":44},"SPONSOR",[95,98],{"name":96,"class":97},"National Institutes of Health (NIH)","NIH",{"name":99,"class":97},"National Cancer Institute (NCI)","100392638","phase-1-d-limonene-radiation-platinumbasedchemo-for-xerostomia-prevention-in-locallyadvanced-hnscc-100392638",false,"NCT04392622","d-Limonene +Radiation +PlatinumBasedChemo for Xerostomia Prevention in LocallyAdvanced HNSCC","A Phase I Study of d-Limonene With Concurrent Radiation and Platinum Based Chemotherapy for Xerostomia Prevention in Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)","Inclusion Criteria:\n\n* Histologically or cytologically confirmed diagnosis of advanced loco regional squamous cell carcinoma of the nasopharynx (AJCC v8 Stage II IV); oropharynx (AJCC v8 Stage I III for HPV+ cancer, excluding T1 2N0; AJCC v8 Stage III IV for Human papillomavirus (HPV) negative cancer); larynx (AJCC v8 Stage III to IV); or hypopharynx (AJCC v8 Stage III to IV), scheduled to undergo chemoradiation. Patients with squamous cell carcinoma of the head and neck from an unknown primary site with involved nodes (N1 to 3) also qualify.\n* Scheduled to received definitive RT with concurrent platinum based chemotherapy at Stanford\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 to 1\n* Must be able to swallow d limonene gelcaps at the time of enrollment.\n* Adequate hepatic function within 2 weeks prior to registration defined as follows: Bilirubin ≤ 2 mg\u002FdL; aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\\u003C 3 times the upper limit of normal\n* Adequate hematologic function within 2 weeks prior to registration defined as follows:\n\n  * Absolute neutrophil count (ANC): ≥ 1,500\u002Fmm3\n  * Platelets: ≥ 100,000\u002Fmm3\n  * Hemoglobin: ≥ 8.0 g\u002FdL (Note: The use of transfusion or other intervention to achieve Hgb ≥ 8.0 g\u002FdL is acceptable).\n* Adequate renal function defined as follows:\n\nSerum creatinine ≤ 1.5 mg\u002FdL within 2 weeks prior to registration or creatinine clearance (CC) ≥ 50 mL\u002Fmin within 2 weeks prior to registration determined by 24 hour collection or estimated by Cockcroft Gault formula:\n\nCCr male = \\[(140 - age) x (wt in kg)\\] \\[(Serum Cr mg\u002FdL) x (72)\\] CCr female = 0.85 x (CrCl male)\n\n* Negative serum pregnancy test within 2 weeks prior to registration and agreement to use a birth control method during the entire duration of d limonene treatment for women of childbearing potential\n* Ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* History of allergic reactions attributed to citrus fruits\n* Pregnant or lactating","ALL","18 Years",{"count":110,"type":111},40,"ESTIMATED","INTERVENTIONAL",[114],"PHASE1","This study explores the safety of d-limonene, a commercially-available dietary supplement (food) as a potential therapeutic for the severe dry mouth (xerostomia) experienced by patients with head and neck cancer as a side effect of their anti-cancer treatment.",[117],"Xerostomia","2025-07-16",{"date":120,"type":121},"2025-07-20","ACTUAL",{"date":123,"type":121},"2021-02-15",{"date":125,"type":111},"2028-05-15",{"name":5,"class":6},1]